Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350956 | 0.89 | PTGS2 (0.34) | CNR2EDNRBEDNRAPIK3CDPIK3CB | |
| SCHEMBL10147511 | 0.78 | MAPK14 (0.36) | MAPK14MAPTMEN1KMT2A | |
| SCHEMBL10146092 | 0.77 | ALDH1A1 (0.36) | MEN1KMT2A | |
| SCHEMBL351120 | 0.76 | CNR2 (0.51) | CNR2CNR1MAPK14MAPTMEN1 | |
| SCHEMBL350815 | 0.76 | CNR2 (0.42) | CNR2CNR1MAPK14MAPT | |
| SCHEMBL352073 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL13618722 | 0.73 | ALDH1A1 (0.34) | MEN1KMT2A | |
| SCHEMBL350081 | 0.71 | CNR2 (0.42) | CNR2CNR1 | |
| SCHEMBL12548113 | 0.68 | NPC1 (0.51) | MAPK14MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12747061 | 0.68 | ALDH1A1 (0.36) | MEN1KMT2APIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | claimed |
| EP-2283001-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | claimed |
| WO-2009140089-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-19 | — | — | WO | claimed |
| EP-2418207-A1 | Sulfone compounds which modulate the CB2 receptor | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418207-A1 | Sulfone compounds which modulate the CB2 receptor | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-2283001-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009140089-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009140089-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885MAPK14 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.